The cytochrome P-450 dependent monooxygenase system plays a pivotal role in both the detoxification and bioactivation of drugs, environmental contaminants, and other potential chemical toxicants. The balance between detoxification and activation is largely dependent on the relative amounts and activities of different isozymes of cytochrome P-450. The long-term objective of the research proposed in this application is to design irreversible inhibitors of specific isozymes of cytochrome P-450. Such isozyme-specific inhibitors could be used in vivo either 1) diagnostically to assess the role of the various cytochromes in mediating or protecting against chemical toxicity or 2) therapeutically to redirect the metabolism of xenobiotics from potentially harmful to innocuous pathways. This proposal will focus on the mechanism, isozyme specificity, and structural requirements of the suicide inactivation of rat liver cytochromes P-450 by dihalomethyl-compounds. The best example of such a compound is the antibiotic chloramphenicol. In contrast to the vast majority of irreversible inhibitors of cytochrome P-450, chloramphenicol acts by virtue of the modification of the protein rather than the heme moiety. Therefore, chloramphenicol and its analogs should prove valuable tools for studying and modulating the various functions of cytochrome P-450. Emphasis will first be placed on elucidation of the mechanism by which rat liver cytochromes P-450 are inactivated upon covalent modification of specific amino acid residues in the proteins by metabolites of chloramphenicol or of its analog 1-p-nitrophenyl-2-dichloroacetamidoethane. Subsequent studies will focus on determining the specificity of dihalomethyl-compounds as inhibitors of different isozymes of rat liver cytochrome P-450 and on elucidating which structural features of the molecules are responsible for their effectiveness and specificity as suicide substrates of cytochromes P-450. Finally, attempts will be made to synthesize specific inhibitors of particular isozymes. These studies should provide the rational basis for the design of isozyme-specific inhibitors for modulating monooxygenase function in humans.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Modified Research Career Development Award (K04)
Project #
5K04ES000151-04
Application #
3072707
Study Section
Toxicology Study Section (TOX)
Project Start
1985-09-27
Project End
1990-08-31
Budget Start
1988-09-01
Budget End
1989-08-31
Support Year
4
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
Schools of Pharmacy
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85722
Kedzie, K M; Balfour, C A; Escobar, G Y et al. (1991) Molecular basis for a functionally unique cytochrome P450IIB1 variant. J Biol Chem 266:22515-21
Green-Thompson, R P; Riddick, D S; Mackie, J E et al. (1991) Porphyrinogenic effects in chick embryo liver cell culture of chloramphenicol analogues that are mechanism-based inactivators of cytochrome P-450. Can J Physiol Pharmacol 69:526-30
Lambert, C; Halpert, J R; Rouleau, J et al. (1991) Effect of congestive heart failure on the intrinsic metabolic capacity of the liver in the dog. Drug Metab Dispos 19:985-9
Kedzie, K M; Philpot, R M; Halpert, J R (1991) Functional expression of mammalian cytochromes P450IIB in the yeast Saccharomyces cerevisiae. Arch Biochem Biophys 291:176-86
Halpert, J R; Stevens, J C (1991) Dihalomethyl compounds as mechanism-based inactivators of cytochromes P450. Methods Enzymol 206:540-8
Ciaccio, P J; Graves, P E; Bourque, D P et al. (1991) cDNA and deduced amino acid sequences of a dog liver cytochrome P-450 of the IIIA gene subfamily. Biochim Biophys Acta 1088:319-22
Halpert, J; Jaw, J Y; Balfour, C et al. (1990) Selective inactivation by chlorofluoroacetamides of the major phenobarbital-inducible form(s) of rat liver cytochrome P-450. Drug Metab Dispos 18:168-74
Halpert, J; Jaw, J Y; Cornfield, L J et al. (1989) Selective inactivation of rat liver cytochromes P-450 by 21-chlorinated steroids. Drug Metab Dispos 17:26-31
Halpert, J R; Jaw, J Y; Johnson, E F (1989) Design of specific mechanism-based inactivators of hepatic and adrenal microsomal cytochromes P-450 responsible for progesterone 21-hydroxylation. Drug Metab Rev 20:645-55
Halpert, J; Jaw, J Y; Balfour, C (1989) Specific inactivation by 17 beta-substituted steroids of rabbit and rat liver cytochromes P-450 responsible for progesterone 21-hydroxylation. Mol Pharmacol 35:148-56

Showing the most recent 10 out of 21 publications